@article{APS10587,
author = {Le-ying Chen and Qing You and Da-zhao Lv and Shuai-hu Li and Shi-yi Zhang},
title = {GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib},
journal = {Acta Pharmacologica Sinica},
volume = {43},
number = {6},
year = {2022},
keywords = {},
abstract = {Many G-protein-coupled receptor (GPCR) agonists have been studied for transactivating epidermal growth factor receptor (EGFR) signaling through extracellular or intracellular pathways. Accumulated evidence has confirmed that GPCR transactivation participates in various diseases. However, the clinical application of GPCR transactivation has not been explored, and more translational studies are needed to develop therapies to target GPCR-mediated EGFR transactivation. In cancer patients treated with EGFR inhibitors (EGFRi), especially afatinib, a unique acneiform rash is frequently developed. In this study, we first established the connection between GPCR transactivation and EGFRi-induced skin disease. We examined the ability of three different GPCR agonists to reverse signaling inhibition and ameliorate rash induced by EGFRi. The activation of different agonists follows unique time and kinase patterns. Rats treated with EGFRi show a similar skin phenotype, with rash occurring in the clinic; correspondingly, treatment with GPCR agonists reduced keratinocyte apoptosis, growth retardation and infiltration of inflammatory cytokines by transactivation. This phenomenon demonstrates that EGFR inhibition in keratinocytes regulates key factors associated with rash. Our findings indicate that maintaining EGFR signaling by GPCR agonists might provide a possible therapy for EGFR inhibitor- induced skin toxicities. Our study provides the first example of the translational application of GPCR transactivation in treating diseases.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10587}
}